Bacil Pharma Limited

Company Profile

Bacil Pharma Limited had its IPO on under the ticker symbol 524516.

The company operates in the Other sector and Other industry. Bacil Pharma Limited has a staff strength of 0 employees.

Stock update

Shares of Bacil Pharma Limited opened at ₹6.51 at the start of the last trading session i.e. 2023-09-13.

The stocks traded within a range of ₹6.51 - ₹6.55, and closed at ₹6.55.

This is a -4.38% slip from the previous day's closing price.

A total volume of 550 shares were traded at the close of the day’s session.

In the last one week, shares of Bacil Pharma Limited have slipped by -16.24%.

Bacil Pharma Limited's Key Ratios

Bacil Pharma Limited has a market cap of ₹35.40 million, indicating a price to book ratio of 2.4212 and a price to sales ratio of 0.

In the last 12-months Bacil Pharma Limited’s revenue was ₹5000 with a gross profit of ₹-45000 and an EBITDA of ₹0. The EBITDA ratio measures Bacil Pharma Limited's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Bacil Pharma Limited’s operating margin was -28108.18% while its return on assets stood at 0% with a return of equity of 0%.

In Q2, Bacil Pharma Limited’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Bacil Pharma Limited’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at ₹-0.456 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Bacil Pharma Limited’s profitability.

Bacil Pharma Limited stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0. Its price to sales ratio in the trailing 12-months stood at 0.

Bacil Pharma Limited stock pays annual dividends of ₹ per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

₹0

Total Liabilities

₹0

Operating Cash Flow

₹0

Capital Expenditure

₹0

Dividend Payout Ratio

0%

Bacil Pharma Limited ended 2024 with ₹0 in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹0 while shareholder equity stood at ₹0.

Bacil Pharma Limited ended 2024 with ₹0 in deferred long-term liabilities, ₹0 in other current liabilities, in common stock, ₹0 in retained earnings and ₹0 in goodwill. Its cash balance stood at ₹0 and cash and short-term investments were ₹0. The company’s total short-term debt was ₹0 while long-term debt stood at ₹0.

Bacil Pharma Limited’s total current assets stands at ₹0 while long-term investments were ₹0 and short-term investments were ₹0. Its net receivables were ₹0 compared to accounts payable of ₹0 and inventory worth ₹0.

In 2024, Bacil Pharma Limited's operating cash flow was ₹0 while its capital expenditure stood at ₹0.

Comparatively, Bacil Pharma Limited paid ₹0 in dividends in 2024.

Other key metrics

Current Trading Price

₹6.55

52-Week High

₹9.82

52-Week Low

₹3.85

Analyst Target Price

₹

Bacil Pharma Limited stock is currently trading at ₹6.55 per share. It touched a 52-week high of ₹9.82 and a 52-week low of ₹9.82. Analysts tracking the stock have a 12-month average target price of ₹.

Its 50-day moving average was ₹7.19 and 200-day moving average was ₹6.49 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 4495.7% of the company’s stock are held by insiders while 0% are held by institutions.